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Abstract 
Human Immunodeficiency Virus has been a major health challenge in many parts of the world. WHO and 
UNAIDS estimated that 35.3 million people were living with HIV at the end of 2012. Sub-Saharan Africa had 
70% of all new HIV infections and Kenya had the third largest population of people living with HIV. In Kenya 
the average national HIV prevalence among people aged 15 – 64 years was at 5.6% in 2012. There are no studies 
that have been carried out in Nyanza province in Kenya to check on point prevalence of HIV in relationship to 
hematological parameters at the ante natal clinic thus a literature gap exists. The aim of this study was to find out 
if there is any effect of human immunodeficiency virus infection on hematological parameters among antenatal 
clinic attendees and also to provide information on the hematological parameters that HIV had an effect on thus 
to show necessity of hematological parameters being part of tests to be carried out in routine ante natal clinic 
exam. The study involved screening of 197 ante natal clinic attendees using normal continuous sampling 
technique. Determine® and Unigold® were used to determine their HIV status. Hematological parameters were 
analyzed using Beckman coulter counter.  Data was collected using questionnaire by interviewing the ante natal 
clinic attendees and individual laboratory results recorded in case report form. Data was analyzed using IBM 
SPSS version 21 the data was expressed as mean + standard error of means. Analysis of Variance (ANOVA) 
was carried out to compare differences between HIV status and hematological parameters.  Results showed that 
majority of the respondents 76.6% 151 were married. Most of the respondents 55.3% 109 had secondary 
education. Majority of the respondent 76.1% were not employed. The results indicated that none of the social 
status was significant with HIV status at P < 0.05 level. HIV status in relation to hematological parameters 
eosinophils was significant at P < 0.05 with a value of 0.015.  Other parameters significant were HCT 0.049, 
MCV at 0.000, MCHC 0.029, Platelets 0.032, MPV 0.002, and PDW 0.008.  The conclusion was that it is 
necessary to have hematological parameters checked as part of the routine ante natal clinic test so as to help treat 
opportunistic infections at an early stage.  
Keywords: Ante natal clinic attendees 
 
1. Introduction 
Human Immunodeficiency Virus (HIV) is a retrovirus that infects immune competent cells causing an 
impairment of host defense. After the introduction of Highly Active Antiretroviral Therapy (HAART) in 1996 
HIV infection epidemiology has changed turned a fatal disease in a treatable chronic infection with an improved 
quality of life and a reduction of morbidity and mortality (Palella et al, 1998). Africa has the largest burden of 
HIV infection and AIDS worldwide (UNAIDS, 2006). WHO and UNAIDS estimates 35.3 million people were 
living with HIV at the end of 2012 (UNAIDS, 2013). Two thirds of HIV infections were in sub-Saharan Africa 
(WHO, 2014). Sub-Saharan Africa had 70% of all new HIV infections in 2012. Kenya had the third largest 
population of people living with HIV in sub-Saharan Africa according to UNAIDS report in 2013. In Kenya, the 
average national HIV prevalence among people aged 15 – 64 years was at 5.6% in 2012 (KAIS 2012). “HIV 
infects and depletes CD4+ T lymphocytes and monocytes /macrophages, putting patients at risk for opportunistic 
infection and malignancy, the major causes of death due to HIV and AIDS” (Hochman et al, 2012). Women are 
most infected by the Acquired Immunodeficiency Syndrome (AIDS) in Africa; a region which accounts for 70% 
of Human Immunodeficiency Virus (HIV) infection (UNAIDS 2009). Current HIV prevention behavioral 
messages on abstinence, faithfulness and condom promotion have had limited impact on HIV incidence rates in 
women, especially in sub-Saharan Africa, where young women bear the greatest HIV burden (Abdool et al, 
2009).  
 
1.1 HIV TRANSMISSION 
HIV is transmitted by three main routes: sexual intercourse, exposure to infected body fluids or tissues and from 
mother to child during pregnancy, delivery or breastfeeding (known as vertical transmission) (Thorne 2007). The 
most frequent mode of transmission of HIV is through sexual intercourse with an infected person. Risk of HIV 
transmission increases in the presence of many sexually transmitted infections (Anderson 2012). HIV 
transmission is directly related to the infected individual’s viral load (Quinn et al, 2000). It is believed that 
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genital ulcers appear to increase the risk approximately by fivefold (Beyrer 2012).  
 
1.2 COURSE OF HIV INFECTION 
There are three main stages of HIV infection: acute infection, clinical latency and AIDS.  
1.2.1 Acute infection 
“The initial period following the contraction of HIV is called acute HIV, primary HIV or acute retroviral 
syndrome” (James et al. 2006). Many individuals develop an influenza like illness or a mononucleosis like 
illness 2 to 4 weeks post exposure while others have no significant symptoms (Marshal 2008). Symptoms occur 
in 40 to 90% of cases and most commonly include fever, large tender lymph nodes, throat inflammation, rash, 
headache and/or sores of the mouth and genitals. Gastrointestinal symptoms such as nausea, vomiting or diarrhea 
may occur as may neurological symptoms of peripheral neuropathy. The duration of the symptoms varies but is 
usually one or two weeks (Vogel et al. 2010). Acute infections are responsible for 89% of HIV transmission 
(Pinkerton 2008). 
1.2.2 Clinical latency 
The initial symptoms are followed by a stage called clinical latency, asymptomatic HIV or chronic HIV. This 
stage can last 3 to over 20 years. While typically there are few or no symptoms at first near the end of this stage 
many people experience fever, weight loss, gastrointestinal problems and muscle pains (Evian 2006). 
1.2.3 Acquired Immunodeficiency Syndrome 
Acquired immunodeficiency syndrome (AIDS) is defined in terms of either a CD4 T cell count below 200 cells 
per µl or the occurrence of specific diseases in association with an HIV infection. The most common initial 
conditions that alert to the presence of AIDS are cachexia in the form of HIV wasting syndrome in (20%) cases 
and esophageal candidiasis. Other common signs include recurring respiratory tract infections (Vogel 2010). 
Opportunistic infections may be caused by bacteria, viruses, fungi and parasites that are normally controlled by 
the immune system (Chu 2011). There are also systemic symptoms such as prolonged fevers, sweats 
(particularly at night), swollen lymph nodes, chills, weakness and weight loss (Sestak 2005). The neurologic 
sequel of HIV range from asymptomatic neurocognitive impairment to minor/moderate cognitive motor disorder 
and HIV-1 associated dementia commonly referred to as HIV-associated neurocognitive disorders (HAND). 
They have been shown to affect 23–50% of those infected with HIV-1 (Joska et al. 2010). Sub-acute AIDS 
encephalitis (SAE), referred to as HIV-associated dementia is characterized pathologically by cerebral atrophy, 
diffuse microglial proliferation and focal microglial nodules, multinucleated giant cells and foci of 
demyelination with associated gliosis (Snider et al. 1983). Clinically, individuals with HIV-associated dementia 
have progressive psychomotor slowing, apathy, memory loss, and difficulty with concentration (Price et al. 
1988).  
 
2. MATERIALS AND METHOD 
2.1 STUDY SITE, AREA AND POPULATION 
The study was conducted at Jaramogi Oginga Odinga Teaching and Referral Hospital in Kisumu. The hospital is 
centrally located in Kisumu County. The hospital is a referral hospital serving the western Kenya region. Kisumu 
city has an approximate population of 578,865 as projected by central bureau of statistics by 2006 in western 
Kenya (Central Bureau of Statistics, 1999). The population served by the hospital is drawn mainly from Kisumu 
town but a substantial part comes from other parts of Kisumu County, neighboring counties and other parts of 
Kenya.  
  
2.2 STUDY DESIGN 
The study was cross sectional descriptive study. 
 
2.3 SAMPLING AND SAMPLE SIZE 
Normal continuous sampling technique was used. Both HIV positive and HIV negative ante natal clinic 
attendee’s samples were collected. 
The sample size was calculated using (Daniel, 1999). 
N = Z2PQ 
          d2 
Where:  
N = the sample size  
Z2 = the standard normal deviate.  
P = proportion in the target population estimated to have characteristic being measured.  
Q = 1 - P           
d = the level of significant set.  
Therefore:  Z = 1.96   
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P = 15.1% proportion of target population which is also the prevalence of HIV in Nyanza ANC. (KAIS, 2012) 
d = 0.05 the level of accuracy.  
N = 1.962 x 0.151 x (1 - 0.151) 
             0.052 
N = 3.8416 x 0.151 x 0.849 
                  0.0025 
N = 196.995      
N ~197 
The sample size was 197. 
 
2.4 DATA COLLECTION TOOLS 
Ante natal clinic attendees filled consent form then a questionnaire was administered.  
 
2.5 LABORATORY PROCEDURE 
The study samples were collected at the JOOTRH ante natal clinic so as to ensure participants confidentiality as 
they attend their regular ANC checkup. Pre testing and post testing counseling was carried out by the counselor 
in the ANC clinic. After informed consent a questionnaire was administered by the ANC nurse. The PI collected 
the blood samples with the assistance of the ANC clinic staff during their regular ANC checks immediately after 
the questionnaire had been filled. ANC attendee were requested to allow blood sample to be collected from the 
vein on their mid arm using aseptic conditions with minimal stasis using a dry, sterile disposable syringe and 
needle. The blood was dispensed into tubes containing the anticoagulant ethylene diamine tetra acetic-acid 
(EDTA). The EDTA (Becton Dickinson, Franklin Lakes NJ) samples were kept at room temperature until 
processing, which was done within 4 hours of collection. 
Routine hematological parameters were done same day they  included total white blood cell count 
(TWBC), differential WBC count percentages for neutrophils, basophils, eosinophils, and monocytes, 
Hemoglobin level (Hb), red blood cell count (RBC), hematocrit (Hct), mean cell volume (MCV), mean cell 
hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), red blood cell distribution width (RDW), 
packed cell volume (PCV), platelet count and mean platelet volume (MPV). The hematological parameters were 
determined using a Coulter A-T Pierce hematology analyzer (Beckman Coulter, Inc. Fullerton, CA. USA). Daily 
quality assurance checks were performed and commercial standards used in accordance with the manufacturer’s 
instructions.  HIV serology was done using Determine™ (Abbot Laboratories, Tokyo, Japan) and Unigold™ 
(Trinity Biotech Plc, Bray, Ireland) for confirmation of positive cases. Each blood sample was mixed well and 
then approximately 20 µl was aspirated by allowing the analyzer’s sampling probe into the blood sample and 
depressing the start button. Results of the analysis were displayed after about 30 seconds after which the 
analyzer generated a paper copy of the results on thermal printing paper. All laboratory results will be recorded 
in the case report form. 
 
2.6 DATA MANAGEMENT AND ANALYSIS 
Data entry management and preliminaries was done in Microsoft Excel™ (2010) spreadsheets software program. 
Other statistical analysis were performed using Statistical Package of Social Sciences (SPSS) version 21 (IBM, 
Armonk, NY, USA) a statistical analysis software. One way ANOVA was used to determine whether there was 
significant difference in the various hematological parameters. Participants were categorized based on their HIV 
status. The descriptive data was presented as means ± standard deviation (SD). A P value of <0.05 was 
considered statistically significant for t-test comparisons. HIV status and hematological parameters were 
compared among participants.  Descriptive, correlation analyses were used with the dependent variable being the 
HIV status and independent variable being hematological parameters. Significant testing was done using chi 
square. Analysis results were presented in form of tables, charts and graphs. 
 
2.7 ETHICAL CONSIDERATIONS 
Approval and permission to carry out the research was requested from the ethical review committee of JOOTRH 
reference number: ERC.1B/VOL.I/143 and Mount Kenya University reference number: 
MKU/DR&D/001/2015/015. Written informed consent was sought from the participants by them filling consent 
form prior to study initiation. Pre testing and post testing counseling was done to all participants individually. 
Participant’s confidentiality was enforced and their names won’t be disclosed nor recorded. Soft copy of the data 
was protected using a password and hard copy protected under lock and key. 
 
3. RESULTS 
A total of 197 ante natal clinic attendees participated in the study. 31(15.7%) were HIV seropositive and 166 
(84.3%) were HIV seronegative. All participants met eligibility criteria for the study. 
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Table 1 Effect of HIV on Hematological Parameters 
HEMATOLOGICAL 
PARAMETERSN=197 
HIV  POS  HIV  NEG  P = 0.05 
 LOW NOR HIGH LOW NOR HIGH  
WBC 7 24 0 18 144 4 0.025 
Neutrophils 15 14 2 69 94 3 0.344 
Lymphocyte 4 20 7 10 119 37 0.288 
Monocyte 11 18 2 70 72 24 0.458 
Eosinophil 16 9 6 98 60 8 0.094 
Basophil  7 24  19 147 0.047 
RBC 20 11 0 58 104 4 0.001 
Hemoglobin 28 3 0 136 28 2 0.123 
HCT 28 3 0 108 54 3 0.002 
MCV 9 16 6 32 131 3 0.297 
MCH 23 1 7 116 4 46 0.302 
MCHC 28 3  119 47  0.014 
RDW  29 2  164 2 0.029 
Platelet 0 28 3 16 146 4 0.005 
PCT 0 31  10 156   
MPV 8 23  12 154   
PDW  23 8  151 15  
Key:  
POS – Positive 
NEG – Negative 
The researcher found out that the hematological parameters that had an effect on HIV status were WBC 
0.025, basophil 0.047, RBC 0.001, HCT 0.002, MCHC 0.014, RDW 0.029 and Platelets 0.005 at P value of 0.05 
levels. 
 
Table 2 HIV Status against Hematological Parameters 
Dependent Variable Independent variable Significance 
P < 0.05 
Status 
(√ - Yes, X – No) 
HIV Status WBC 0.146 X 
HIV Status Neutrophils 0.209 X 
HIV Status Lymphocytes 0.384 X 
HIV Status Monocytes 0.248 X 
HIV Status Eosinophils 0.015 √ 
HIV Status Basophils 0.093 X 
HIV Status RBS 0.007 √ 
HIV Status HB 0.484 X 
HIV Status HCT 0.049 √ 
HIV Status MCV 0.000 √ 
HIV Status MCH 0.822 X 
HIV Status MCHC 0.029 √ 
HIV Status RDW 0.057 X 
HIV Status Platelets 0.032 √ 
HIV Status PCT 0.374 X 
HIV Status MPV 0.002 √ 
HIV Status PDW 0.008 √ 
HIV Status PCT 0.184 X 
The researcher did cross tabulation on HIV status * Hematological indices and found out that eosinophil 
was significant at P < 0.05 with a value of 0.015.  Other parameters which were significant were HCT 0.049, 
MCV at 0.000, MCHC 0.029, Platelets 0.032, MPV 0.002 and PDW 0.008. The rest did not show any level of 
significance as shown on the table above.  
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Table 3 HEMATOLOGICAL PARAMETERS 
Descriptive _1_Hematological parameters 
HIV status WBC Neutrophils Lymphocytes Monocytes Eosinophils Basophils RBC MCH 
HIV 
positive 
N 31 31 31 31 31 31 31 31 
Mean 1.774 1.581 2.097 1.710 1.677 2.77 1.355 1.484 
Std. Error of 
Mean 
.0763 .1114 .1073 .1057 .1421 .076 .0874 .1529 
Std. Deviation .4250 .6204 .5975 .5884 .7911 .425 .4864 .8513 
% of Total Sum 14.7% 15.6% 15.3% 15.6% 17.7% 15.2% 13.1% 14.9% 
HIV 
negative 
N 166 166 166 166 166 166 166 166 
Mean 1.916 1.602 2.163 1.723 1.458 2.89 1.675 1.578 
Std. Error of 
Mean 
.0276 .0409 .0394 .0545 .0457 .025 .0403 .0695 
Std. Deviation .3552 .5266 .5082 .7017 .5888 .319 .5189 .8961 
% of Total Sum 85.3% 84.4% 84.7% 84.4% 82.3% 84.8% 86.9% 85.1% 
 
Descriptives_2_Hematological parameters 
HIV status HB HCT MCV MCHC RDW Platelets PCT MPV PDW 
HIV positive N 31 31 31 31 31 31 31 31 31 
Mean 
count 
1.097 1.097 1.903 1.097 2.065 2.10 2.0000 1.742 2.258 
Std. Error 
of Mean 
.0540 .0540 .1258 .0540 .0449 .054 .00000 .0799 .0799 
Std. 
Deviation 
.3005 .3005 .7002 .3005 .2497 .301 .00000 .4448 .4448 
% of Total 
Sum 
14.7% 11.3% 16.3% 13.8% 16.1% 16.9% 16.2% 14.4% 16.8% 
HIV 
negative 
N 166 166 166 166 166 166 166 166 166 
Mean 
count 
1.193 1.605 1.825 1.283 2.012 1.93 1.9352 1.928 2.090 
Std. Error 
of Mean 
.0330 .2451 .0331 .0351 .0085 .026 .02037 .0202 .0223 
Std. 
Deviation 
.4252 3.1579 .4259 .4519 .1094 .341 .26246 .2597 .2876 
% of Total 
Sum 
85.3% 88.7% 83.7% 86.2% 83.9% 83.1% 83.8% 85.6% 83.2% 
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Table 4 
ANOVA Table 
   Sum of 
Squares df 
Mean 
Square F Sig. 
WBC * HIV status Between Groups (Combined) .523 1 .523 3.885 .040 
Within Groups 26.239 195 .135   
Total 26.761 196    
Neutrophils * HIV 
status 
Between Groups (Combined) .012 1 .012 .042 .838 
Within Groups 57.307 195 .294   
Total 57.320 196    
Lymphocytes * 
HIV status 
Between Groups (Combined) .113 1 .113 .415 .520 
Within Groups 53.318 195 .273   
Total 53.431 196    
Monocytes * HIV 
status 
Between Groups (Combined) .005 1 .005 .010 .922 
Within Groups 91.640 195 .470   
Total 91.645 196    
Eosinophils * HIV 
status 
Between Groups (Combined) 1.260 1 1.260 3.233 .074 
Within Groups 75.979 195 .390   
Total 77.239 196    
Basophils * HIV 
status 
Between Groups (Combined) .324 1 .324 2.839 .094 
Within Groups 22.245 195 .114   
Total 22.569 196    
RBC * HIV status Between Groups (Combined) 2.673 1 2.673 10.113 .002 
Within Groups 51.531 195 .264   
Total 54.203 196    
HB * HIV status Between Groups (Combined) .241 1 .241 1.443 .231 
Within Groups 32.541 195 .167   
Total 32.782 196    
HCT * HIV status Between Groups (Combined) 6.758 1 6.758 .800 .372 
Within Groups 1648.115 195 8.452   
Total 1654.873 196    
MCV * HIV status Between Groups (Combined) .159 1 .159 .693 .406 
Within Groups 44.643 195 .229   
Total 44.802 196    
MCH * HIV status Between Groups (Combined) .233 1 .233 .295 .588 
Within Groups 154.224 195 .791   
Total 154.457 196    
MCHC * HIV 
status 
Between Groups (Combined) .907 1 .907 4.860 .029 
Within Groups 36.402 195 .187   
Total 37.310 196    
RDW * HIV status Between Groups (Combined) .072 1 .072 3.645 .058 
Within Groups 3.847 195 .020   
Total 3.919 196    
Platelets * HIV 
status 
Between Groups (Combined) .747 1 .747 6.666 .011 
Within Groups 21.842 195 .112   
Total 22.589 196    
PCT * HIV status Between Groups (Combined) .110 1 .110 1.879 .172 
Within Groups 11.366 195 .058   
Total 11.476 196    
MPV * HIV status Between Groups (Combined) .902 1 .902 10.300 .002 
Within Groups 17.068 195 .088   
Total 17.970 196    
PDW * HIV status Between Groups (Combined) .735 1 .735 7.317 .007 
Within Groups 19.580 195 .100   
Total 20.315 196    
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4. DISCUSSION 
HIV prevalence was at 15.7% (31 participants were HIV positive) at JOOTRH ANC clinic in 2014. Kenya adult 
HIV prevalence among people aged 15 to 64 as per the KAIS studies in 2012 were at 5.6%. Sentential study in 
ANC in 2010 Nyanza had a prevalence of 17.9% while country wide 7.6% ANC attendees were positive (Kenya 
National Bureau of Statistics 2010). This is a 2.2% difference between JOOTRH in 2014 against Nyanza in 2010 
study. Our study was carried out in Nyanza Province, western Kenya and it is also the region with the highest 
HIV prevalence in Kenya (15%) (KAIS, 2012). There was correlation between HIV status and WBC, basophils, 
RBC, HTC, MCHC, RDW, platelets, MPV and PDW. There was effect of HIV on various hematological 
parameters, they had a p value greater than 0.05. They included neutrophils, lymphocytes, monocytes, eosinophil, 
hemoglobin, MCV and MCH for the participants who were HIV positive. Hematological parameters and 
eosinophil was significant at P < 0.05 with a value of 0.015.  Other parameters which were significant were HCT 
0.049, MCV at 0.000, MCHC 0.029, Platelets 0.032, MPV 0.002 and PDW 0.008. Similar with other African 
studies, (Kibaya et al, 2008) was a high eosinophil and low WBC and neutrophil values.  The eosinophilia may 
be attributed to increased parasitemia, since our study area is endemic for schistosomiasis, helminthic infections 
and perennial malaria (Handzel et al, 2003). Eosinophil counts were much lower than two studies within the 
region which screened participants from a rural population (Zeh et al, 2011). The low neutrophil count observed 
in our population could possibly be attributed to African genetics, environment or diet (Ezeilo, 1974). Low MCV 
is an indirect marker of iron deficiency (Tefferi, 2003). Hb values were much higher than those from a study 
within the same region that screened out malaria infected participants (Kibaya et al, 2008). There was effect of 
HIV on various hematological parameters and they had a p value greater than 0.05. This included neutrophils, 
lymphocytes, monocytes, eosinophil, hemoglobin, MCV and MCH for the participants who were HIV positive. 
Leucocytes increased in number in response to introduction of foreign particles in the body such as an infection. 
The leucocytes that were determined included: eosinophils, neutrophils, basophils, monocytes and lymphocytes. 
Previous studies have shown that eosinophils are produced in large numbers during parasite infection. Reduced 
levels of eosinophils denote a reduced immunity (Butterwort et al. 1997). Eosinophil mediated cytotoxixity is not 
enhanced by lymphocytes, monocytes and neutrophils (Butterwort et al. 1997). 
  
5. CONCLUSION AND RECOMENDATION 
 The researcher found out that the hematological factors that had effect on HIV status were WBC 0.025, 
basophils 0.047, RBC 0.001, HCT 0.002, MCHC 0.014, RDW 0.029 and Platelets 0.005 at P, 0.05 level. 15.7 % 
were HIV positive thus an increase as compared to KAIS study in 2012. It will be necessary to add the 
hematological parameters as part of HIV monitoring while carrying out the CD4 values. Prenatal HIV screening 
is accurate; more evidence is needed to fully understand short- and long-term maternal and infant effects in 
regards to hematological parameters. Given that the number of persons receiving ante natal clinical services who 
are HIV positive is expected to increase substantially in sub-Saharan Africa, there is a need for the evaluation of 
hematological parameters in the laboratory to ensure appropriate general health assessment, treatment 
monitoring, and efficient implementation of HIV management. The study recommend that WBC, basophils, 
RBC, HTC, MCHC, RDW, platelets, MPV and PDW be estimated in the HIV positive individuals when they 
come for ANC as the study results indicate that they are affected. This will aid in management of opportunistic 
infections. The government should formulate policy to include hematological indices in HIV monitoring. More 
research is needed to understand the clinical significance of the hematologic abnormalities. Pregnant women 
should be offered screening for anaemia. Screening should take place early in pregnancy (at the booking 
appointment) and at 28 weeks when other blood screening tests are being performed. This allows enough time 
for treatment if anaemia is detected. Hemoglobin levels outside the normal range for pregnancy (that is, 11 g/100 
ml at first contact and 10.5 g/100 ml at 28 weeks) should be investigated and iron supplementation considered if 
indicated.  If the mean corpuscular hemoglobin is below 27 picograms, laboratory screening (preferably high-
performance liquid chromatography) should be offered. 
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